Amylin design debate heats up as Lilly’s crucial mid-stage weight loss data near
Thursday, August 20 – In the amylin race, drug design appears to be a key differentiator.
Later this year, Novo Nordisk’s CagriSema is likely to become the first approved drug containing an amylin analog and a GLP-1 agonist to …
How cost and perception could reshape the GLP-1 market
Thursday, August 20 – As Eli Lilly and Novo Nordisk race for share, surveys show affordability and prescribing preferences may help decide the winners.
GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause
Wednesday, August 19 – (MedPage Today) — Experts suggested that GLP-1 agonists may reduce the effectiveness of birth control pills. (The Hill)
A phase III trial of avexitide, a first-in-class GLP-1 receptor antagonist, met its primary endpoint of reducing low blood…
Amylyx reports Phase 3 win for GLP-1 antagonist avexitide in post-bariatric hypoglycemia
Wednesday, August 19 – After a turbulent few years researching ALS, Amylyx Pharmaceuticals said it has notched a success in its attempt to rebuild as a GLP-1 biotech.
A Phase 3 study for avexitide, a GLP-1 receptor antagonist, hit …
Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia
Wednesday, August 19 – With a Phase 3 trial showing a reduction of serious and severe hypoglycemic episodes in patients who have undergone weight loss surgery, Amylyx Pharmaceuticals plans to file for approval this year. If granted market entry, avexitide could hit peak sales of $1.7 billion worldwide, analysts estimate.
FDA takes aim at misleading online claims for compounded GLP-1 drugs
Saturday, July 4 – On June 16, 2026, the US Food and Drug Administration (FDA) issued 25 warning letters to various telehealth companies alleging that their websites contained false or misleading claims about compounded semaglutide, tirzepatide, and, in one case, liraglutide products….By: McDermott Will & Schulte
Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like
Tuesday, May 19 – Semaglutide for Weight Loss Without Diabetes: What the Approval Covers, What Programs Skip, and What Results Actually Look Like